Docetaxel Injection, Solution, Concentrate
Product Images NDC 71288-133

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 71288-133). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Doc08 0000 01 V2)

Chemical structure diagram of Docetaxel, illustrating the molecular arrangement of atoms and bonds characteristic of this active pharmaceutical ingredient.*

FDA Label Image

Figure 1 (Doc08 0000 02 V2)

A Kaplan-Meier plot depicting Disease-Free Survival (DFS) probability over time in months. The chart compares two groups labeled 'TAC' and 'FAC' using solid and dotted lines respectively, showing percentage DFS on the vertical axis and time on the horizontal axis up to 66 months.*

FDA Label Image

Figure 2 (Doc08 0000 03 V2)

A survival probability curve chart comparing two treatment groups labeled TAC and FAC over a survival time span of up to 66 months. The y-axis represents survival probability in percentage, while the x-axis shows survival time in months.*

FDA Label Image

Figure 3 (Doc08 0000 04)

A survival curve graph showing overall survival probability over time in months. The graph compares two groups labeled T75 and BSC, plotting cumulative probability on the Y-axis against survival time on the X-axis, with a log-rank p-value of 0.010 indicating statistical comparison.*

FDA Label Image

Figure 4 (Doc08 0000 05)

A Kaplan-Meier survival curve showing cumulative probability over survival time in months. The chart compares overall survival between two groups labeled T75 and V/I with a log-rank p-value of 0.13.*

FDA Label Image

Figure 5 (Doc08 0000 06 V3)

A survival probability curve graph depicting survival time in months on the x-axis and survival probability on the y-axis. Two lines compare different treatment groups labeled T75 q3w and M q3w, showing changes in survival probability over time up to 30 months.*

FDA Label Image

Figure 6 (Doc08 0000 07 V2)

A line chart showing survival or probability curves over time (months) for two groups labeled TCF and CF. The vertical axis represents probability percentage from 0 to 100%, and the horizontal axis represents time up to 24 months. The chart compares the probability trends of TCF and CF over the time period.*

FDA Label Image

Figure 7 (Doc08 0000 08 V2)

A Kaplan-Meier survival curve chart showing survival probability (%) over time in months (0 to 36). Two lines are displayed: a solid line labeled TCF and a dotted line labeled CF, indicating comparisons of survival outcomes between the two groups.*

FDA Label Image

Figure 8 (Doc08 0000 09 V3)

A Kaplan-Meier survival curve chart comparing progression-free survival (PFS) probability over time in months between two groups labeled TPF and PF. The graph displays PFS probability percentages on the vertical axis and progression-free survival time up to 42 months on the horizontal axis with TPF showing higher survival probabilities than PF.*

FDA Label Image

Figure 9 (Doc08 0000 10 V2)

A survival probability chart comparing two treatment groups labeled TPF and PF over time in months. The y-axis shows survival probability as a percentage, and the x-axis shows survival time up to 72 months. The TPF group has a higher survival curve than the PF group throughout the time period.*

FDA Label Image

Figure 10 (Doc08 0000 11 V2)

A survival probability Kaplan-Meier curve comparing two groups labeled TPF and PF with patient counts shown over survival time in months up to 72 months. The solid line represents TPF group with 255 patients initially, and the dotted line represents PF group with 246 patients initially, depicting survival probability trends over time.*

FDA Label Image

Principal Display Panel – Docetaxel Injection, Usp, 20 mg Per mL Vial Label (Doc08 0000 12 V4)

Label for Docetaxel Injection, USP 20 mg per mL, an intravenous injection solution concentrate. The 1 mL single-dose vial is ready to add to infusion solution. Label includes cautions, storage instructions, manufacturer Meitheal Pharmaceuticals Inc., and states the product is made in China.*

FDA Label Image

Principal Display Panel – Docetaxel Injection, Usp, 20 mg Per mL Carton (Doc08 0000 13 V4)

Label for Docetaxel Injection, USP 20 mg per mL concentrate for intravenous use. The label includes warnings that it is a cytotoxic agent and instructions that it is ready to add to infusion solution. The packaging indicates a single-dose vial of 1 mL and is labeled by Meitheal Pharmaceuticals Inc.*

FDA Label Image

Principal Display Panel – Docetaxel Injection, Usp, 80 mg Per 4 mL Vial Label (Doc08 0000 14 V4)

Docetaxel Injection, USP 20 mg/mL solution concentrate for intravenous use in a 4 mL single-dose vial. The label indicates 80 mg per 4 mL total dosage, cautions it as a cytotoxic agent, and instructs to add to infusion solution. Manufactured by Meitheal Pharmaceuticals Inc., packaged with storage instructions and formulation details.*

FDA Label Image

Principal Display Panel – Docetaxel Injection, Usp, 80 mg Per 4 mL Carton (Doc08 0000 15 V4)

Docetaxel Injection, USP 20 mg/mL (80 mg per 4 mL) concentrate for intravenous use in a single-dose vial. The label indicates it is ready to add to infusion solution and warns that the drug is a cytotoxic agent. Labeler is Meitheal Pharmaceuticals Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.